Newsbenzinga
Werewolf Therapeutics Takes Aim At Untapped Pain Market With Ambros Deal
· Published
Article summary
Werewolf Therapeutics and Ambros Therapeutics merge in an all-stock deal with $150M in financing to advance Phase 3 CRPS-1 candidate.
An excerpt from the original article.
Comments —
Loading comments…